
Alzamend Neuro (ALZN) Stock Forecast & Price Target
Alzamend Neuro (ALZN) Analyst Ratings
Bulls say
Alzamend Neuro Inc. has reported positive top-line results from its studies in June 2023, reinforcing confidence in its therapeutic developments for neurodegenerative diseases. The company's innovative drug candidates, AL001 and AL002, aim to address critical medical needs in the treatment of conditions such as Alzheimer's disease, positioning it favorably within the biopharmaceutical market. Additionally, the current valuation of Alzamend Neuro is deemed attractive, with analysts indicating that the achievement of upcoming key milestones and positive data could serve as significant catalysts for the stock's performance.
Bears say
Alzamend Neuro Inc reported a net loss of $2.7 million, translating to an earnings per share (EPS) of $(1.28), which considerably exceeded the company's previous estimates of $(0.69). The company faces significant challenges related to balance sheet and liquidity risks, as well as the potential failure of its drug candidates to demonstrate safety and efficacy in clinical trials, which could hinder regulatory approvals and commercialization efforts. Additionally, external factors such as competition, shifting macroeconomic conditions, and changing healthcare priorities could further complicate the company's prospects and undermine investor confidence in its stock.
This aggregate rating is based on analysts' research of Alzamend Neuro and is not a guaranteed prediction by Public.com or investment advice.
Alzamend Neuro (ALZN) Analyst Forecast & Price Prediction
Start investing in Alzamend Neuro (ALZN)
Order type
Buy in
Order amount
Est. shares
0 shares